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INTRODUCTION
Familial Mediterranean fever (FMF) (OMIM #249100) is a genetic disease with autosomalrecessive inheritance. The disease most commonly occurs in Arabs, Jews, Armenians and Turks (1) . FMF is clinically characterized by recurrent and self-limited attacks of fever accompanied by peritonitis, pleuritis, synovitis or erysipelas-like erythema and may be complicated by AA amyloidosis. Colchicine was found to be very effective in preventing attacks of FMF and in the development of amyloidosis (2) .
The responsible gene, MEFV, has been mapped to chromosome 16p13.3 and consists of 10 exons and encodes a 781 amino acid protein called Pyrin which is expressed in granulocytes and is thought to be a negative regulator of inflammation. Since the cloning of the MEFV gene (3, 4) , about 244 sequence variants for MEFV have been described (5) . Five founding mutations M694V, V726A, M680I, M694I (in exon 10) and E148Q (in exon 2) are the most frequently encountered mutations and account for 74% of FMF mutations in typical patients (6) . In Syrian FMF patients, the most frequent mutation is M694V (36.5%), followed by V726A (15.2%), E148Q (14.5%), M680I (G/C) (13.2%), and M694I (10.2%) mutations (7).
The clinical implications of different MEFV mutations (e.g. M694V, M694I and M680I (G>C)) in FMF have been clearly implicated (3, 4, 7) . However, the clinical implication of E148Q mutation is still controversial. Initially, E148Q was described as a disease causing mutation with low penetrance and mild symptoms (8, 9) , but in more recent studies some investigators found a similar frequency of E148Q among patients and controls and therefore suggested that it is no more than a benign polymorphism (10, 11) . The carrier frequency of E148Q is 7.93% in Syrians (Rami Jarjour and Rami Abou Jamra, unpublished data), 5% in Lebanese (12), 12% in Turks (13) and 10% in Ashkenazi Jews (14) . E148Q and Familial Mediterranean Fever 4 The main aim of this study was to evaluate the clinical implications of E148Q mutation in FMF patients and compare it with other FMF-causing mutations.
PATIENTS AND METHODS
A total of 787 Syrian FMF patients were referred to the Clinical Genetics Unit, Atomic Energy Out of the 787 FMF patients, records of 137 unrelated FMF patients with E148Q mutation were retrospectively reviewed. The disease severity was evaluated according to the previously described criteria (16) and assigned to 1 of 3 severity levels (mild, intermediate, or severe). Every patient was informed about the study and a written consent was signed either by the patient or his/her parent for blood sampling. This study has been approved by the Institutional Review Board of the Atomic Energy Commission of Syria (AECS).
For all patients, EDTA blood was sampled and DNA was isolated from frozen blood samples by the phenol-chlorophorm extraction method (17) .
MEFV mutation analysis was performed for 12 mutations using a reverse-hybridization assay (FMF StripAssay™) according to the manufacturer's instructions (ViennaLab Labordiagnostika, Vienna, Austria).
Statistical analysis
Differences between groups were assessed using Z-test for two proportions and T-test for means.
All P values were 2-tailed, and confidence intervals (CIs) were set at 95%. A P value <0.05 was accepted as statistically significant.
RESULTS
Among the 137 FMF patients with E148Q mutation, 72 (52.6%) were males and 65 (47.4%) were females (female to male ratio was 0.9) ( Table I) The main clinical characteristics of the patients were as follows (Table I) In a previous study, the author identified the frequency and distribution of 12 MEFV mutations in 97 Syrian patients and performed a genotype-phenotype correlation in the patients' cohort (7). The following MEFV mutations were investigated: E148Q in exon 2, P369S in exon 3, F479L in exon 5, M680I (G/C), M680I (G/A), I692del, M694V, M694I, K695R, V726A, A744S and R761H in exon 10. The most frequent mutation was M694V (36.5%), followed by V726A (15.2%), E148Q (14.5%), M680I (G/C) (13.2%), and M694I (10.2%) mutations. Rare mutations (R761H, A744S, M680I (G/A), K695R, P369S, F479L and I692del) were also detected in the patients. M694V was associated with the severe form of the disease.
In order to evaluate the clinical features of the patients in this study, the clinical features were compared to that in the previous study (Table I ). There were statistical significant differences between these two groups regarding age of onset, fever, arthritis, attacks frequency/year, and duration of attacks.. However, there were no statistical significant differences between male/female ratio, abdominal pain, nausea, vomiting, diarrhea, chest pain, erysipelaslike erythema, myalgia, family history and response to colchicine (table I) The severity of the disease was assessed in all 137 patients (Table I ). There were statistically significance differences between the mean severity scores of this cohort and the previous cohort especially between the severely affected patients in both groups. Moreover, the mildly affected patients in both groups showed a statistically significant difference (Table I) .
In order to compare the clinical features of the FMF patients with E148Q mutation, 137 patients were divided into three groups according to the presence of the E148Q mutation on both alleles (E148Q/E148Q) (homozygote) (Group A), on one allele with other identified mutation (E148Q/+) (compound heterozygote) (Group B) and on one allele without other identified mutation (E148Q/-) (heterozygote) (Group C) ( Table 2 ). There were no statistically significant differences between these 3 groups regarding age of onset, abdominal pain, nausea, vomiting, diarrhea, fever, chest pain, arthralgia, arthritis, erysipelas-like erythema, myalgia, response to colchicines, attacks frequency/year, and duration of attacks. However, there were statistically significant differences between groups B and C regarding the family history and the severity score (intermediate).
DISCUSSION
E148Q mutation is one of the most common mutations in FMF patients. Initially, E148Q was described as a disease-causing MEFV mutation with low penetrance and mild symptoms (8, 9) .
Patients who are homozygous for E148Q, have a heterogeneous clinical presentation and may be at risk of developing amyloidosis (18) . However, the role of E148Q in FMF is controversial. In more recent studies some investigators found a similar frequency of E148Q among patients and controls and therefore suggested that it is no more than a benign polymorphism (10,11). Others could not provide evidence that would support the notion that E148Q is a mutation or a polymorphism (19) .
A recent study using a quantum chemistry model showed that the impact of the E148Q on the structure of pyrin is indeed low but not zero (20) . This study concluded that the E148Q variation is associated with a mild effect on the structure and perhaps the function of the pyrin.
Since there is no biochemical testing for FMF, the diagnosis of this genetic disease is still clinical. E148Q may have a potential role in other diseases. A recent study has shown that E148Q is a promising candidate risk factor for multiple sclerosis (21) . E148Q is the most frequent mutation in patients with behcet's disease (22,23). In China, it has been shown that E148Q is associated with Henoch-Schönlein purpura (24) . This study aimed to investigate the association between E148Q and FMF based on the clinical features of the patients carrying this mutation.
The clinical features of FMF in the patients with E148Q in this study (group I) are not different from those we previously reported in FMF patients with different MEFV mutations (group II) (7) ( Table I) . Peritonitis was the most common symptom in this study (95.62%). Fever is the second most common symptom in this study (70.8%). However, there is a clear difference in terms of severity between the E148Q patients (group I) and those with other mutations (group II) ( Table I ). The difference in severity score could be mainly explained by the presence of the M694V mutation in the other group (II) of FMF patients which is associated with severe form of the disease, early onset, high frequency of attacks and higher frequencies of arthritis as we and others have previously shown (7, 25) . The data from this study show that E148Q causes mild symptoms of FMF while other MEFV mutations are associated with the severe form of FMF.
The rate of amyloidosis in the Syrian FMF patients is low (ranges 0-5%) (7, 26) . This might be due to the fact that these data were obtained after the introduction of colchicine as a recommended treatment for FMF. None of the 137 patients in this study had amyloidosis.
However, FMF associated amyloidosis in patients who are heterozygote for E148Q has been reported (27) . It should be noted that there was no significant difference regarding response to colchicine treatment between groups I and II (Table I ). This notion is of great value as response to colchicine is one of the criteria of diagnosis of FMF (28) . This suggests that E148Q might be a disease-causing mutation.
There were no significant statistical differences between patients with homozygote E148Q mutation (group A), compound heterozygote (group B) or heterozygote (group C) (table   II) . This shows that there were no differences between the homozygote patients (Group A) and the other two groups (B and C) regarding the clinical features. Moreover, there was no difference between the heterozygote patients (group C) and the other two groups (A and B) . Recently, it has been reported that a detection of a single MEFV mutation is sufficient if the presence of clinical symptoms for the diagnosis of FMF and the initiation of a trial of colchicines (29, 30) . Moreover, a recent report has shown that the clinical picture of French heterozygote patients with recurrent fevers resembles that of homozygote patients. This report has also shown that E148Q accounts for 15% of those heterozygote patients (31) . Our data are in contestant with what it has been previously published. Therefore, the author suggests that patients who are heterozygous or homozygous for E148Q should be considered as FMF patients and treated with colchicine.
In conclusion, this study showed that E148Q variant is associated with FMF. Moreover, patients with E148Q should not be ignored and should be followed-up and treated liked other FMF patients.
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